Quantcast

Industry news that matters to you.  Learn more

Archives for July 2012

Agilent Technologies Collaborates with Gachon University on Discovery of Biomarkers for Cancer and Diabetes

Agilent Technologies Inc. (NYSE: A) and Gachon University of Medicine and Science today announced a collaboration in the field of biomarker discovery using proteomics and glycoproteomics. The College of Pharmacy at Gachon University is world-renowned for its research in preventing and treating cancer and diabetes.

Bio-Rad and Myriad RBM Partner to Commercialize Multiplex Biomarker Kits for Life Science Research

Bio Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics Inc. (NASDAQ: MYGN), and a leading multiplex biomarker testing company, today announced that they have partnered to develop and distribute high-quality immunoassay kits. Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.

Tegal Driving Market Growth for Interpretive Content, Focusing on Genomics-based Medicine

Tegal Corporation recently announced that it would acquire CollabRx, Inc., a privately held technology company that uses information technology to inform personalized cancer treatment planning by combining knowledge of new therapies with expert insight. The acquisition was completed yesterday (July 16th, 2012).

TGen Method Isolates Biospecimens for Treatment of Kidney Disease

Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.

Using Biomarkers to Identify and Treat Schizophrenia

In the current online issue of PLoS ONE, researchers at the University of California, San Diego School of Medicine say they have identified a set of laboratory-based biomarkers that can be useful for understanding brain-based abnormalities in schizophrenia. The measurements, known as endophenotypes, could ultimately be a boon to clinicians who sometimes struggle to recognize and treat the complex and confounding mental disorder.